Stock comparison
Bioventus
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BVS
Bioventus
Market cap
$628.7M
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BVS | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 36D | 75B | IDXX |
| Benjamin Graham | 52D | 80A | IDXX |
| Philip Fisher | 41D | 75B | IDXX |
| Peter Lynch | 29F | 71B | IDXX |
| Joel Greenblatt | 26F | 83C | IDXX |
| Charlie Munger | 38D | 87A | IDXX |
| Terry Smith | 34F | 84A | IDXX |
Side-by-side metrics
| Metric | BVS | IDXX |
|---|---|---|
| Market cap | $628.7M | $44.12B |
| P/E (TTM) | 25.0x | 39.0x |
| EV/EBIT | 12.0x | 31.6x |
| ROIC (TTM) | 11.77% | 40.66% |
| Gross margin | 67.78% | 62.05% |
| Net margin | 4.94% | 24.63% |
| Revenue CAGR 5y | 7.15% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.1x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BVS leads on
- Debt / Equity0.1xvs 0.7x+86%
- EV/EBIT12.0xvs 31.6x+62%
- P/E (TTM)25.0xvs 39.0x+36%
- Gross margin67.78%vs 62.05%+8%
IDXX leads on
- Market cap$44.12Bvs $628.7M+99%
- Net margin24.63%vs 4.94%+80%
- ROIC (TTM)40.66%vs 11.77%+71%
- Revenue CAGR 5y7.56%vs 7.15%+5%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.